Understanding why some people respond differently to GLP-1 based diabetes treatments

The transition from a conceptual, mechanism-informed framework to actual clinical deployment requires confronting several barriers. First, mechanistic type assignment must rely on simple, low-cost signals, such as early HbA1c and weight changes at 4–6 weeks, prior response to DPP-4 inhibitors, diabetes duration, and the presence of gastrointestinal adverse events, to avoid dependence on high-cost biomarkers or imaging. Second, workflow integration is critical: any algorithm demanding frequent laboratory testing or specialized software risks rapid abandonment in routine practice. Third, cost-effectiveness and clinical inertia remain major obstacles; history shows that complex predictive tools, even when accurate, rarely survive if they slow decision-making or lack reimbursement pathways. To balance these realities, we outline a two-tier approach: a pragmatic, clinic-ready tier using easily accessible parameters for preliminary stratification, and a research-intensive tier (with C-peptide dynamics, CGM-derived postprandial profiles, and exploratory biomarkers), reserved for prospective studies. This design favors feasibility over perfection, positioning the framework as a heuristic for hypothesis generation rather than an immediate prescriptive algorithm.